| August 1, 2026 |
BMRN |
Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia |
Trial Milestone |
Phase 3 |
| August 3, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| August 3, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| August 3, 2026 |
MRK |
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017) |
Trial Milestone |
Phase 2 |
| August 3, 2026 |
MRK |
A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037) |
Trial Milestone |
Phase 3 |
| August 3, 2026 |
LLY |
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis |
Trial Milestone |
Phase 2 |
| August 3, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| August 3, 2026 |
ARGX |
6-K filed: Foreign issuer report |
Filing |
— |
| August 3, 2026 |
BNTX |
6-K filed: Foreign issuer report |
Filing |
— |
| August 3, 2026 |
AAPG |
6-K filed: Foreign issuer report |
Filing |
— |
| August 3, 2026 |
JAZZ |
Quarterly results filed (8-K) |
Earnings |
— |
| August 3, 2026 |
INBS |
8-K filed: Reg FD disclosure |
Filing |
— |
| August 3, 2026 |
INBS |
8-K filed: Other event |
Filing |
— |
| August 3, 2026 |
ALKS |
8-K/A filed: Leadership change |
Corporate |
— |
| August 3, 2026 |
TGTX |
Quarterly results filed (8-K) |
Earnings |
— |
| August 3, 2026 |
OCUL |
Quarterly results filed (8-K) |
Earnings |
— |
| August 3, 2026 |
EIKN |
8-K filed: Leadership change |
Corporate |
— |
| August 3, 2026 |
CANF |
6-K filed: Foreign issuer report |
Filing |
— |
| August 3, 2026 |
SUPN |
8-K filed: Other event |
Filing |
— |
| August 3, 2026 |
SUPN |
8-K filed: Other event |
Filing |
— |
| August 3, 2026 |
SUPN |
Quarterly results filed (8-K) |
Earnings |
— |
| August 3, 2026 |
SUPN |
8-K filed: Material agreement, Leadership change, Other event |
Corporate |
— |
| August 3, 2026 |
LNTH |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| August 3, 2026 |
GKOS |
8-K filed: Reg FD disclosure |
Filing |
— |
| August 3, 2026 |
KRYS |
Quarterly results filed (8-K) |
Earnings |
— |
| August 3, 2026 |
CRBP |
A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity |
Trial Milestone |
Phase 1 |
| August 3, 2026 |
STOK |
8-K filed: Other event |
Filing |
— |
| August 3, 2026 |
STOK |
Quarterly results filed (8-K) |
Earnings |
— |
| August 3, 2026 |
ORIC |
Quarterly results filed (8-K) |
Earnings |
— |
| August 3, 2026 |
CRSP |
Quarterly results filed (8-K) |
Earnings |
— |
| August 3, 2026 |
CATX |
8-K filed: Other event |
Filing |
— |
| August 3, 2026 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| August 3, 2026 |
AMRX |
8-K filed: Material agreement |
Corporate |
— |
| August 3, 2026 |
VRTX |
Quarterly results filed (8-K) |
Earnings |
— |
| August 3, 2026 |
LPCN |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| August 3, 2026 |
MBRX |
8-K filed: Material agreement |
Corporate |
— |
| August 3, 2026 |
LTRN |
8-K filed: Reg FD disclosure |
Filing |
— |
| August 3, 2026 |
ALZN |
8-K filed: Material agreement, Listing / standard notice |
Corporate |
— |
| August 3, 2026 |
GNPX |
8-K filed: Other event |
Filing |
— |
| August 4, 2026 |
MRK |
Quarterly results filed (8-K) |
Earnings |
— |
| August 4, 2026 |
PFE |
Quarterly results filed (8-K) |
Earnings |
— |
| August 4, 2026 |
JNJ |
8-K filed: Leadership change |
Corporate |
— |
| August 4, 2026 |
AMGN |
Quarterly results filed (8-K) |
Earnings |
— |
| August 4, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| August 4, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| August 4, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| August 4, 2026 |
GILD |
Quarterly results filed (8-K) |
Earnings |
— |
| August 4, 2026 |
BNTX |
6-K filed: Foreign issuer report |
Filing |
— |
| August 4, 2026 |
BNTX |
6-K filed: Foreign issuer report |
Filing |
— |
| August 4, 2026 |
RARE |
Quarterly results filed (8-K) |
Earnings |
— |
| August 4, 2026 |
IBRX |
Quarterly results filed (8-K) |
Earnings |
— |
| August 4, 2026 |
ARWR |
Quarterly results filed (8-K) |
Earnings |
— |
| August 4, 2026 |
IDYA |
Quarterly results filed (8-K) |
Earnings |
— |
| August 4, 2026 |
ACAD |
Quarterly results filed (8-K) |
Earnings |
— |
| August 4, 2026 |
RYTM |
Quarterly results filed (8-K) |
Earnings |
— |
| August 4, 2026 |
DNTH |
Quarterly results filed (8-K) |
Earnings |
— |
| August 4, 2026 |
TVTX |
Quarterly results filed (8-K) |
Earnings |
— |
| August 4, 2026 |
PVLA |
Quarterly results filed (8-K) |
Earnings |
— |
| August 4, 2026 |
LNTH |
8-K filed: Material agreement, Leadership change |
Corporate |
— |
| August 4, 2026 |
SNDX |
Quarterly results filed (8-K) |
Earnings |
— |
| August 4, 2026 |
BEAM |
Quarterly results filed (8-K) |
Earnings |
— |
| August 4, 2026 |
OTLC |
8-K filed: Material agreement |
Corporate |
— |
| August 4, 2026 |
TLSA |
6-K filed: Foreign issuer report |
Filing |
— |
| August 4, 2026 |
TYRA |
Quarterly results filed (8-K) |
Earnings |
— |
| August 4, 2026 |
PCRX |
Quarterly results filed (8-K) |
Earnings |
— |
| August 4, 2026 |
LRMR |
Quarterly results filed (8-K) |
Earnings |
— |
| August 4, 2026 |
SYRE |
Quarterly results filed (8-K) |
Earnings |
— |
| August 4, 2026 |
RNXT |
8-K filed: Other event |
Filing |
— |
| August 4, 2026 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| August 4, 2026 |
LPCN |
Quarterly results filed (8-K) |
Earnings |
— |
| August 4, 2026 |
PGEN |
Quarterly results filed (8-K) |
Earnings |
— |
| August 4, 2026 |
FTH |
Quarterly results filed (8-K) |
Earnings |
— |
| August 4, 2026 |
SXTP |
8-K filed: Material agreement, Other event |
Corporate |
— |
| August 4, 2026 |
RIGL |
Quarterly results filed (8-K) |
Earnings |
— |
| August 5, 2026 |
LLY |
Quarterly results filed (8-K) |
Earnings |
— |
| August 5, 2026 |
ABBV |
8-K filed: Other event |
Filing |
— |
| August 5, 2026 |
ONC |
Quarterly results filed (8-K) |
Earnings |
— |
| August 5, 2026 |
VNDA |
Quarterly results filed (8-K) |
Earnings |
— |
| August 5, 2026 |
EXEL |
Quarterly results filed (8-K) |
Earnings |
— |
| August 5, 2026 |
AAPG |
6-K filed: Foreign issuer report |
Filing |
— |
| August 5, 2026 |
RVMD |
Quarterly results filed (8-K) |
Earnings |
— |
| August 5, 2026 |
INBS |
8-K filed: Reg FD disclosure |
Filing |
— |
| August 5, 2026 |
MRNA |
mFLUSIVA (mRNA-1010) — FDA PDUFA Decision |
Regulatory |
BLA |
| August 5, 2026 |
MIRM |
Quarterly results filed (8-K) |
Earnings |
— |
| August 5, 2026 |
SMMT |
8-K filed: Other event |
Filing |
— |
| August 5, 2026 |
EYPT |
Quarterly results filed (8-K) |
Earnings |
— |
| August 5, 2026 |
PCVX |
Quarterly results filed (8-K) |
Earnings |
— |
| August 5, 2026 |
VIR |
Quarterly results filed (8-K) |
Earnings |
— |
| August 5, 2026 |
SRPT |
Quarterly results filed (8-K) |
Earnings |
— |
| August 5, 2026 |
URGN |
Quarterly results filed (8-K) |
Earnings |
— |
| August 5, 2026 |
RAPP |
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder |
Trial Milestone |
Phase 2 |
| August 5, 2026 |
RAPP |
Quarterly results filed (8-K) |
Earnings |
— |
| August 5, 2026 |
RCUS |
Quarterly results filed (8-K) |
Earnings |
— |
| August 5, 2026 |
VTGN |
8-K filed: Listing / standard notice |
Corporate |
— |
| August 5, 2026 |
CMPS |
Quarterly results filed (8-K) |
Earnings |
— |
| August 5, 2026 |
PTGX |
Quarterly results filed (8-K) |
Earnings |
— |
| August 5, 2026 |
UTHR |
Quarterly results filed (8-K) |
Earnings |
— |
| August 5, 2026 |
IMRX |
Quarterly results filed (8-K) |
Earnings |
— |
| August 5, 2026 |
RXRX |
Quarterly results filed (8-K) |
Earnings |
— |
| August 5, 2026 |
BCRX |
Quarterly results filed (8-K) |
Earnings |
— |
| August 5, 2026 |
KYMR |
Quarterly results filed (8-K) |
Earnings |
— |
| August 5, 2026 |
BTMD |
Quarterly results filed (8-K) |
Earnings |
— |
| August 5, 2026 |
TRDA |
Quarterly results filed (8-K) |
Earnings |
— |
| August 5, 2026 |
CRDL |
6-K filed: Foreign issuer report |
Filing |
— |
| August 5, 2026 |
MNKD |
Quarterly results filed (8-K) |
Earnings |
— |
| August 5, 2026 |
EDIT |
Quarterly results filed (8-K) |
Earnings |
— |
| August 5, 2026 |
ACIU |
6-K filed: Foreign issuer report |
Filing |
— |
| August 5, 2026 |
AKBA |
Quarterly results filed (8-K) |
Earnings |
— |
| August 5, 2026 |
XNCR |
Quarterly results filed (8-K) |
Earnings |
— |
| August 5, 2026 |
BIOA |
Quarterly results filed (8-K) |
Earnings |
— |
| August 5, 2026 |
QTTB |
Quarterly results filed (8-K) |
Earnings |
— |
| August 5, 2026 |
BDTX |
Quarterly results filed (8-K) |
Earnings |
— |
| August 5, 2026 |
GNPX |
8-K filed: Listing / standard notice |
Corporate |
— |
| August 6, 2026 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| August 6, 2026 |
TAK |
6-K filed: Foreign issuer report |
Filing |
— |
| August 6, 2026 |
BMRN |
Quarterly results filed (8-K) |
Earnings |
— |
| August 6, 2026 |
PRAX |
Quarterly results filed (8-K) |
Earnings |
— |
| August 6, 2026 |
NUVB |
Quarterly results filed (8-K) |
Earnings |
— |
| August 6, 2026 |
XENE |
Quarterly results filed (8-K) |
Earnings |
— |
| August 6, 2026 |
INSM |
Quarterly results filed (8-K) |
Earnings |
— |
| August 6, 2026 |
DFTX |
Quarterly results filed (8-K) |
Earnings |
— |
| August 6, 2026 |
VSTM |
Quarterly results filed (8-K) |
Earnings |
— |
| August 6, 2026 |
OCGN |
Quarterly results filed (8-K) |
Earnings |
— |
| August 6, 2026 |
CLDX |
Quarterly results filed (8-K) |
Earnings |
— |
| August 6, 2026 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| August 6, 2026 |
CYTK |
Quarterly results filed (8-K) |
Earnings |
— |
| August 6, 2026 |
NTLA |
Quarterly results filed (8-K) |
Earnings |
— |
| August 6, 2026 |
IOVA |
8-K filed: Other event |
Filing |
— |
| August 6, 2026 |
IOVA |
Quarterly results filed (8-K) |
Earnings |
— |
| August 6, 2026 |
VRCA |
Quarterly results filed (8-K) |
Earnings |
— |
| August 6, 2026 |
IMVT |
Quarterly results filed (8-K) |
Earnings |
— |
| August 6, 2026 |
VTRS |
Quarterly results filed (8-K) |
Earnings |
— |
| August 6, 2026 |
RGNX |
Quarterly results filed (8-K) |
Earnings |
— |
| August 6, 2026 |
ANNX |
8-K filed: Other event |
Filing |
— |
| August 6, 2026 |
IMCR |
Quarterly results filed (8-K) |
Earnings |
— |
| August 6, 2026 |
LNTH |
Quarterly results filed (8-K) |
Earnings |
— |
| August 6, 2026 |
VTGN |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| August 6, 2026 |
DNLI |
Quarterly results filed (8-K) |
Earnings |
— |
| August 6, 2026 |
SGP |
Quarterly results filed (8-K) |
Earnings |
— |
| August 6, 2026 |
CGON |
Quarterly results filed (8-K) |
Earnings |
— |
| August 6, 2026 |
RNAC |
Quarterly results filed (8-K) |
Earnings |
— |
| August 6, 2026 |
TRVI |
Quarterly results filed (8-K) |
Earnings |
— |
| August 6, 2026 |
IRD |
Quarterly results filed (8-K) |
Earnings |
— |
| August 6, 2026 |
ALXO |
Quarterly results filed (8-K) |
Earnings |
— |
| August 6, 2026 |
OCS |
6-K filed: Foreign issuer report |
Filing |
— |
| August 6, 2026 |
GENB |
Quarterly results filed (8-K) |
Earnings |
— |
| August 6, 2026 |
GERN |
Quarterly results filed (8-K) |
Earnings |
— |
| August 6, 2026 |
GRCE |
8-K filed: Material agreement, Other event |
Corporate |
— |
| August 6, 2026 |
CRBP |
Quarterly results filed (8-K) |
Earnings |
— |
| August 6, 2026 |
DCTH |
Quarterly results filed (8-K) |
Earnings |
— |
| August 6, 2026 |
SLDB |
8-K filed: Other event |
Filing |
— |
| August 6, 2026 |
LYEL |
Quarterly results filed (8-K) |
Earnings |
— |
| August 6, 2026 |
SRRK |
8-K filed: Other event |
Filing |
— |
| August 6, 2026 |
SRRK |
Quarterly results filed (8-K) |
Earnings |
— |
| August 6, 2026 |
RLMD |
Quarterly results filed (8-K) |
Earnings |
— |
| August 6, 2026 |
AMLX |
Quarterly results filed (8-K) |
Earnings |
— |
| August 6, 2026 |
TNGX |
8-K filed: Leadership change |
Corporate |
— |
| August 6, 2026 |
EWTX |
Quarterly results filed (8-K) |
Earnings |
— |
| August 6, 2026 |
MBX |
Quarterly results filed (8-K) |
Earnings |
— |
| August 6, 2026 |
TLSA |
6-K filed: Foreign issuer report |
Filing |
— |
| August 6, 2026 |
PBH |
Quarterly results filed (8-K) |
Earnings |
— |
| August 6, 2026 |
RLAY |
Quarterly results filed (8-K) |
Earnings |
— |
| August 6, 2026 |
CRVS |
Quarterly results filed (8-K) |
Earnings |
— |
| August 6, 2026 |
VTVT |
Quarterly results filed (8-K) |
Earnings |
— |
| August 6, 2026 |
CLYM |
Quarterly results filed (8-K) |
Earnings |
— |
| August 6, 2026 |
PBYI |
Quarterly results filed (8-K) |
Earnings |
— |
| August 6, 2026 |
HALO |
Quarterly results filed (8-K) |
Earnings |
— |
| August 6, 2026 |
ARDX |
Quarterly results filed (8-K) |
Earnings |
— |
| August 6, 2026 |
LXRX |
Quarterly results filed (8-K) |
Earnings |
— |
| August 6, 2026 |
ENSC |
8-K filed: Material agreement, Acquisition completed, Leadership change, Reg FD disclosure |
Corporate |
— |
| August 6, 2026 |
AGEN |
Quarterly results filed (8-K) |
Earnings |
— |
| August 6, 2026 |
CLLS |
6-K filed: Foreign issuer report |
Filing |
— |
| August 6, 2026 |
CLLS |
6-K filed: Foreign issuer report |
Filing |
— |
| August 6, 2026 |
CGEM |
Quarterly results filed (8-K) |
Earnings |
— |
| August 7, 2026 |
INCY |
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis |
Trial Milestone |
Phase 3 |
| August 7, 2026 |
VSTM |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| August 7, 2026 |
REPL |
8-K filed: Other event |
Filing |
— |
| August 7, 2026 |
TNGX |
8-K/A filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| August 7, 2026 |
NERV |
Quarterly results filed (8-K) |
Earnings |
— |
| August 7, 2026 |
COYA |
8-K/A filed: Leadership change |
Corporate |
— |
| August 7, 2026 |
OKYO |
Results filed (20-F/A) |
Earnings |
— |
| August 7, 2026 |
CRMD |
8-K filed: Other event |
Filing |
— |
| August 7, 2026 |
TMCI |
Quarterly results filed (8-K) |
Earnings |
— |
| August 7, 2026 |
KPRX |
Quarterly results filed (8-K) |
Earnings |
— |
| August 7, 2026 |
ILMN |
8-K filed: Other event |
Filing |
— |
| August 10, 2026 |
AZN |
Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an Ileostomy |
Trial Milestone |
Phase 2 |
| August 10, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| August 10, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| August 10, 2026 |
JAZZ |
8-K filed: Material agreement |
Corporate |
— |
| August 10, 2026 |
JAZZ |
8-K filed: Reg FD disclosure |
Filing |
— |
| August 10, 2026 |
AXSM |
Quarterly results filed (8-K) |
Earnings |
— |
| August 10, 2026 |
REPL |
8-K filed: Other event |
Filing |
— |
| August 10, 2026 |
MLTX |
Quarterly results filed (8-K) |
Earnings |
— |
| August 10, 2026 |
ANNX |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| August 10, 2026 |
TENX |
8-K filed: Other event |
Filing |
— |
| August 10, 2026 |
COGT |
8-K filed: Other event |
Filing |
— |
| August 10, 2026 |
COGT |
Quarterly results filed (8-K) |
Earnings |
— |
| August 10, 2026 |
OLMA |
Quarterly results filed (8-K) |
Earnings |
— |
| August 10, 2026 |
OCS |
6-K filed: Foreign issuer report |
Filing |
— |
| August 10, 2026 |
ORKA |
Quarterly results filed (8-K) |
Earnings |
— |
| August 10, 2026 |
ALMS |
8-K filed: Other event |
Filing |
— |
| August 10, 2026 |
VERA |
Quarterly results filed (8-K) |
Earnings |
— |
| August 10, 2026 |
PROK |
Quarterly results filed (8-K) |
Earnings |
— |
| August 10, 2026 |
CATX |
Quarterly results filed (8-K) |
Earnings |
— |
| August 10, 2026 |
NTHI |
Quarterly results filed (8-K) |
Earnings |
— |
| August 10, 2026 |
DMAC |
Quarterly results filed (8-K) |
Earnings |
— |
| August 10, 2026 |
AMRX |
8-K filed: Material agreement, Acquisition completed, Reg FD disclosure |
Corporate |
— |
| August 10, 2026 |
ERAS |
8-K filed: Leadership change |
Corporate |
— |
| August 10, 2026 |
NKTX |
Quarterly results filed (8-K) |
Earnings |
— |
| August 11, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| August 11, 2026 |
RARE |
8-K filed: Other event |
Filing |
— |
| August 11, 2026 |
INBS |
8-K filed: Reg FD disclosure |
Filing |
— |
| August 11, 2026 |
TSHA |
Quarterly results filed (8-K) |
Earnings |
— |
| August 11, 2026 |
MANE |
Quarterly results filed (8-K) |
Earnings |
— |
| August 11, 2026 |
REPL |
8-K/A filed: Other event |
Filing |
— |
| August 11, 2026 |
KARD |
Quarterly results filed (8-K) |
Earnings |
— |
| August 11, 2026 |
TARA |
Quarterly results filed (8-K) |
Earnings |
— |
| August 11, 2026 |
IMUX |
Quarterly results filed (8-K) |
Earnings |
— |
| August 11, 2026 |
LBRX |
Quarterly results filed (8-K) |
Earnings |
— |
| August 11, 2026 |
IKT |
Quarterly results filed (8-K) |
Earnings |
— |
| August 11, 2026 |
BLTE |
6-K filed: Foreign issuer report |
Filing |
— |
| August 11, 2026 |
IMNN |
8-K filed: Leadership change |
Corporate |
— |
| August 11, 2026 |
IMNN |
Quarterly results filed (8-K) |
Earnings |
— |
| August 11, 2026 |
TNGX |
8-K filed: Other event |
Filing |
— |
| August 11, 2026 |
TNGX |
Quarterly results filed (8-K) |
Earnings |
— |
| August 11, 2026 |
BCAX |
Quarterly results filed (8-K) |
Earnings |
— |
| August 11, 2026 |
SLS |
Quarterly results filed (8-K) |
Earnings |
— |
| August 11, 2026 |
AURA |
Quarterly results filed (8-K) |
Earnings |
— |
| August 11, 2026 |
KYTX |
Quarterly results filed (8-K) |
Earnings |
— |
| August 11, 2026 |
NGNE |
Quarterly results filed (8-K) |
Earnings |
— |
| August 11, 2026 |
INTS |
Quarterly results filed (8-K) |
Earnings |
— |
| August 11, 2026 |
COAG |
Quarterly results filed (8-K) |
Earnings |
— |
| August 11, 2026 |
SGMT |
Quarterly results filed (8-K) |
Earnings |
— |
| August 11, 2026 |
MLYS |
Quarterly results filed (8-K) |
Earnings |
— |
| August 11, 2026 |
COYA |
Quarterly results filed (8-K) |
Earnings |
— |
| August 11, 2026 |
ACHV |
Quarterly results filed (8-K) |
Earnings |
— |
| August 11, 2026 |
ERAS |
Quarterly results filed (8-K) |
Earnings |
— |
| August 11, 2026 |
IMNM |
Quarterly results filed (8-K) |
Earnings |
— |
| August 11, 2026 |
ACIU |
6-K filed: Foreign issuer report |
Filing |
— |
| August 11, 2026 |
AGEN |
8-K filed: Leadership change |
Corporate |
— |
| August 11, 2026 |
MAZE |
Quarterly results filed (8-K) |
Earnings |
— |
| August 12, 2026 |
ARGX |
A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS) |
Trial Milestone |
Phase 2 |
| August 12, 2026 |
ALKS |
8-K filed: Material agreement |
Corporate |
— |
| August 12, 2026 |
DFTX |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| August 12, 2026 |
KLRA |
Quarterly results filed (8-K) |
Earnings |
— |
| August 12, 2026 |
MDGL |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| August 12, 2026 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| August 12, 2026 |
PHAR |
Leniolisib for Immune Dysregulation in CVID |
Trial Milestone |
Phase 2 |
| August 12, 2026 |
LQDA |
Quarterly results filed (8-K) |
Earnings |
— |
| August 12, 2026 |
ANNX |
Quarterly results filed (8-K) |
Earnings |
— |
| August 12, 2026 |
CANF |
6-K filed: Foreign issuer report |
Filing |
— |
| August 12, 2026 |
HUMA |
Quarterly results filed (8-K) |
Earnings |
— |
| August 12, 2026 |
AVIR |
Quarterly results filed (8-K) |
Earnings |
— |
| August 12, 2026 |
AVBP |
Quarterly results filed (8-K) |
Earnings |
— |
| August 12, 2026 |
PHVS |
6-K filed: Foreign issuer report |
Filing |
— |
| August 12, 2026 |
KURA |
Quarterly results filed (8-K) |
Earnings |
— |
| August 12, 2026 |
ALT |
Quarterly results filed (8-K) |
Earnings |
— |
| August 12, 2026 |
ANRO |
Quarterly results filed (8-K) |
Earnings |
— |
| August 12, 2026 |
LXEO |
Quarterly results filed (8-K) |
Earnings |
— |
| August 12, 2026 |
AVLN |
Quarterly results filed (8-K) |
Earnings |
— |
| August 12, 2026 |
OMER |
Quarterly results filed (8-K) |
Earnings |
— |
| August 12, 2026 |
TTRX |
Quarterly results filed (8-K) |
Earnings |
— |
| August 12, 2026 |
NTHI |
8-K filed: Reg FD disclosure |
Filing |
— |
| August 12, 2026 |
NERV |
8-K filed: Leadership change |
Corporate |
— |
| August 12, 2026 |
RVPH |
Quarterly results filed (8-K) |
Earnings |
— |
| August 12, 2026 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| August 12, 2026 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| August 12, 2026 |
VRTX |
An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias (RUBY-4) |
Trial Milestone |
Phase 1/Phase 2 |
| August 12, 2026 |
OTLK |
Quarterly results filed (8-K) |
Earnings |
— |
| August 12, 2026 |
CRDL |
6-K filed: Foreign issuer report |
Filing |
— |
| August 12, 2026 |
TCRX |
Quarterly results filed (8-K) |
Earnings |
— |
| August 12, 2026 |
SPRB |
Quarterly results filed (8-K) |
Earnings |
— |
| August 12, 2026 |
AKBA |
To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis |
Trial Milestone |
Phase 3 |
| August 12, 2026 |
ACRV |
Quarterly results filed (8-K) |
Earnings |
— |
| August 12, 2026 |
ALLO |
Quarterly results filed (8-K) |
Earnings |
— |
| August 12, 2026 |
APLM |
6-K filed: Foreign issuer report |
Filing |
— |
| August 12, 2026 |
ILMN |
8-K filed: Other event |
Filing |
— |
| August 13, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| August 13, 2026 |
AAPG |
6-K filed: Foreign issuer report |
Filing |
— |
| August 13, 2026 |
FDMT |
Quarterly results filed (8-K) |
Earnings |
— |
| August 13, 2026 |
KPTI |
Quarterly results filed (8-K) |
Earnings |
— |
| August 13, 2026 |
ZBIO |
Quarterly results filed (8-K) |
Earnings |
— |
| August 13, 2026 |
DFTX |
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama) |
Trial Milestone |
Phase 3 |
| August 13, 2026 |
KOD |
Quarterly results filed (8-K) |
Earnings |
— |
| August 13, 2026 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| August 13, 2026 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| August 13, 2026 |
CYTK |
8-K filed: Other event |
Filing |
— |
| August 13, 2026 |
EIKN |
Quarterly results filed (8-K) |
Earnings |
— |
| August 13, 2026 |
PHAR |
6-K filed: Foreign issuer report |
Filing |
— |
| August 13, 2026 |
CABA |
Quarterly results filed (8-K) |
Earnings |
— |
| August 13, 2026 |
CADL |
Quarterly results filed (8-K) |
Earnings |
— |
| August 13, 2026 |
CORT |
Evaluation of Miricorilant on Liver Fat in Patients With MASLD |
Trial Milestone |
Phase 1 |
| August 13, 2026 |
NKTR |
Quarterly results filed (8-K) |
Earnings |
— |
| August 13, 2026 |
MGTX |
Quarterly results filed (8-K) |
Earnings |
— |
| August 13, 2026 |
MDWD |
6-K filed: Foreign issuer report |
Filing |
— |
| August 13, 2026 |
BLTE |
6-K filed: Foreign issuer report |
Filing |
— |
| August 13, 2026 |
OLMA |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| August 13, 2026 |
IVVD |
Quarterly results filed (8-K) |
Earnings |
— |
| August 13, 2026 |
GRCE |
Quarterly results filed (8-K) |
Earnings |
— |
| August 13, 2026 |
ALMS |
Quarterly results filed (8-K) |
Earnings |
— |
| August 13, 2026 |
PRQR |
6-K filed: Foreign issuer report |
Filing |
— |
| August 13, 2026 |
PRQR |
6-K filed: Foreign issuer report |
Filing |
— |
| August 13, 2026 |
CAPR |
Quarterly results filed (8-K) |
Earnings |
— |
| August 13, 2026 |
ELDN |
Quarterly results filed (8-K) |
Earnings |
— |
| August 13, 2026 |
CLRB |
Quarterly results filed (8-K) |
Earnings |
— |
| August 13, 2026 |
KYNB |
Quarterly results filed (8-K) |
Earnings |
— |
| August 13, 2026 |
BFRI |
Quarterly results filed (8-K) |
Earnings |
— |
| August 13, 2026 |
ABEO |
Quarterly results filed (8-K) |
Earnings |
— |
| August 13, 2026 |
OMER |
8-K filed: Leadership change |
Corporate |
— |
| August 13, 2026 |
RNXT |
Quarterly results filed (8-K) |
Earnings |
— |
| August 13, 2026 |
MPLT |
Quarterly results filed (8-K) |
Earnings |
— |
| August 13, 2026 |
VALN |
6-K filed: Foreign issuer report |
Filing |
— |
| August 13, 2026 |
NTHI |
8-K filed: Reg FD disclosure |
Filing |
— |
| August 13, 2026 |
SGMT |
8-K filed: Other event |
Filing |
— |
| August 13, 2026 |
NGEN |
6-K filed: Foreign issuer report |
Filing |
— |
| August 13, 2026 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| August 13, 2026 |
CRMD |
Quarterly results filed (8-K) |
Earnings |
— |
| August 13, 2026 |
TPST |
Quarterly results filed (8-K) |
Earnings |
— |
| August 13, 2026 |
TPST |
8-K filed: Material agreement |
Corporate |
— |
| August 13, 2026 |
ENSC |
Quarterly results filed (8-K) |
Earnings |
— |
| August 13, 2026 |
GOSS |
Quarterly results filed (8-K) |
Earnings |
— |
| August 13, 2026 |
FATE |
Quarterly results filed (8-K) |
Earnings |
— |
| August 13, 2026 |
AGEN |
8-K filed: Leadership change |
Corporate |
— |
| August 13, 2026 |
CGEM |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| August 13, 2026 |
ILMN |
8-K filed: Material agreement |
Corporate |
— |
| August 14, 2026 |
QNRX |
Quarterly results filed (8-K) |
Earnings |
— |
| August 14, 2026 |
EIKN |
8-K filed: Reg FD disclosure |
Filing |
— |
| August 14, 2026 |
REPL |
Quarterly results filed (8-K) |
Earnings |
— |
| August 14, 2026 |
ANVS |
Quarterly results filed (8-K) |
Earnings |
— |
| August 14, 2026 |
VTGN |
Quarterly results filed (8-K) |
Earnings |
— |
| August 14, 2026 |
ATNM |
8-K filed: Listing / standard notice, Reg FD disclosure |
Corporate |
— |
| August 14, 2026 |
PBH |
8-K filed: Leadership change |
Corporate |
— |
| August 14, 2026 |
LONA |
Quarterly results filed (8-K) |
Earnings |
— |
| August 14, 2026 |
CLYM |
8-K filed: Other event |
Filing |
— |
| August 14, 2026 |
TRAW |
Quarterly results filed (8-K) |
Earnings |
— |
| August 14, 2026 |
VALN |
6-K filed: Foreign issuer report |
Filing |
— |
| August 14, 2026 |
BCLI |
Quarterly results filed (8-K) |
Earnings |
— |
| August 14, 2026 |
ACHV |
8-K filed: Other event |
Filing |
— |
| August 14, 2026 |
BYSI |
Quarterly results filed (8-K) |
Earnings |
— |
| August 14, 2026 |
OTLK |
8-K filed: Other event |
Filing |
— |
| August 14, 2026 |
OTLK |
Quarterly results filed (8-K) |
Earnings |
— |
| August 14, 2026 |
HURA |
Quarterly results filed (8-K) |
Earnings |
— |
| August 14, 2026 |
MBRX |
Quarterly results filed (8-K) |
Earnings |
— |
| August 14, 2026 |
CNSY |
Quarterly results filed (8-K) |
Earnings |
— |
| August 14, 2026 |
LTRN |
Quarterly results filed (8-K) |
Earnings |
— |
| August 15, 2026 |
ABBV |
A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors |
Trial Milestone |
Phase 1 |
| August 15, 2026 |
ABBV |
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) |
Trial Milestone |
Phase 2 |
| August 15, 2026 |
ARGX |
A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG) |
Trial Milestone |
Phase 4 |
| August 15, 2026 |
MIRM |
A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4) |
Trial Milestone |
Phase 3 |
| August 15, 2026 |
KOD |
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK |
Trial Milestone |
Phase 3 |
| August 15, 2026 |
MANE |
Safety and Efficacy of VDPHL01 in Males and Females With AGA |
Trial Milestone |
Phase 2 |
| August 15, 2026 |
CORT |
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers |
Trial Milestone |
Phase 2 |
| August 15, 2026 |
BCYC |
Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression |
Trial Milestone |
Phase 1/Phase 2 |
| August 15, 2026 |
GKOS |
Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone |
Trial Milestone |
Phase 4 |
| August 15, 2026 |
AVIR |
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone |
Trial Milestone |
Phase 1 |
| August 15, 2026 |
IVVD |
Study of VYD2311 for the Prevention of COVID-19 |
Trial Milestone |
Phase 3 |
| August 15, 2026 |
IVVD |
Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine |
Trial Milestone |
Phase 3 |
| August 15, 2026 |
PHVS |
Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE |
Trial Milestone |
Phase 3 |
| August 15, 2026 |
ENSC |
PF614 Analgesic Activity in Acute Postoperative Pain (PF614-301) |
Trial Milestone |
Phase 3 |
| August 15, 2026 |
RIGL |
Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) |
Trial Milestone |
Phase 1/Phase 2 |
| August 17, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| August 17, 2026 |
AZN |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| August 17, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| August 17, 2026 |
ABBV |
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children |
Trial Milestone |
Phase 2 |
| August 17, 2026 |
ARGX |
6-K filed: Foreign issuer report |
Filing |
— |
| August 17, 2026 |
SVA |
6-K filed: Foreign issuer report |
Filing |
— |
| August 17, 2026 |
BMRN |
Rapid Drug Desensitization Study in Adults Experiencing Hypersensitivity Reactions to Palynziq |
Trial Milestone |
Phase 4 |
| August 17, 2026 |
EYPT |
8-K filed: Other event |
Filing |
— |
| August 17, 2026 |
CANF |
6-K filed: Foreign issuer report |
Filing |
— |
| August 17, 2026 |
TTRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| August 17, 2026 |
ARDX |
8-K filed: Other event |
Filing |
— |
| August 17, 2026 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| August 17, 2026 |
MAZE |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| August 17, 2026 |
DRUG |
6-K filed: Foreign issuer report |
Filing |
— |
| August 17, 2026 |
ILMN |
8-K filed: Other event |
Filing |
— |
| August 18, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| August 18, 2026 |
ABBV |
8-K filed: Other event |
Filing |
— |
| August 18, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| August 18, 2026 |
BNTX |
Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors |
Trial Milestone |
Phase 1 |
| August 18, 2026 |
BMRN |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| August 18, 2026 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| August 18, 2026 |
AMLX |
8-K filed: Other event |
Filing |
— |
| August 18, 2026 |
AMLX |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| August 18, 2026 |
IMTX |
6-K filed: Foreign issuer report |
Filing |
— |
| August 18, 2026 |
ONCY |
8-K filed: Other event |
Filing |
— |
| August 18, 2026 |
HALO |
8-K filed: Leadership change |
Corporate |
— |
| August 18, 2026 |
BLRX |
6-K filed: Foreign issuer report |
Filing |
— |
| August 18, 2026 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| August 18, 2026 |
TPST |
8-K filed: Other event |
Filing |
— |
| August 18, 2026 |
AGEN |
8-K filed: Material agreement |
Corporate |
— |
| August 18, 2026 |
GNPX |
8-K filed: Other event |
Filing |
— |
| August 19, 2026 |
AZN |
6-K filed: Corporate announcement |
Corporate |
— |
| August 19, 2026 |
RARE |
8-K filed: Other event |
Filing |
— |
| August 19, 2026 |
BMRN |
Study of BMN 349 Single Dose in PiZZ and PiMZ/MASH Adult Participants |
Trial Milestone |
Phase 1 |
| August 19, 2026 |
INBS |
Quarterly results filed (8-K) |
Earnings |
— |
| August 19, 2026 |
MRNA |
Intismeran Autogene — Phase 3 INTerpath-001 (Melanoma) |
Trial Readout |
Phase 3 |
| August 19, 2026 |
MNOV |
8-K filed: Leadership change |
Corporate |
— |
| August 19, 2026 |
SYRE |
A Study of SPY002-091 in Healthy Volunteers |
Trial Milestone |
Phase 1 |
| August 19, 2026 |
MCUJF |
6-K filed: Foreign issuer report |
Filing |
— |
| August 19, 2026 |
MCUJF |
6-K filed: Foreign issuer report |
Filing |
— |
| August 19, 2026 |
KPRX |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| August 20, 2026 |
BNTX |
6-K filed: Foreign issuer report |
Filing |
— |
| August 20, 2026 |
AAPG |
6-K filed: Foreign issuer report |
Filing |
— |
| August 20, 2026 |
QNRX |
8-K filed: Leadership change, Other event |
Corporate |
— |
| August 20, 2026 |
URGN |
8-K filed: Other event |
Filing |
— |
| August 20, 2026 |
BCYC |
8-K filed: Leadership change |
Corporate |
— |
| August 20, 2026 |
ORKA |
ORKA-002-211 A Phase I Study to Evaluate ORKA-002 in Healthy Volunteers Following A Single Dose |
Trial Milestone |
Phase 1 |
| August 20, 2026 |
AMLX |
8-K filed: Material agreement |
Corporate |
— |
| August 20, 2026 |
RNXT |
8-K filed: Other event |
Filing |
— |
| August 20, 2026 |
ARDX |
Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years |
Trial Milestone |
Phase 3 |
| August 20, 2026 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| August 20, 2026 |
ACIU |
6-K filed: Foreign issuer report |
Filing |
— |
| August 21, 2026 |
PFE |
A Study to Learn How Different Amounts of the Study Medicine Called PF-07999415 Are Tolerated and Act in the Body in Healthy Adults |
Trial Milestone |
Phase 1 |
| August 21, 2026 |
NTHI |
8-K/A filed: Leadership change |
Corporate |
— |
| August 21, 2026 |
LPCN |
8-K/A filed: Leadership change |
Corporate |
— |
| August 21, 2026 |
GOSS |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| August 21, 2026 |
MNKD |
8-K filed: Other event |
Filing |
— |
| August 24, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| August 24, 2026 |
GSK |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| August 24, 2026 |
GSK |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| August 24, 2026 |
REGN |
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery |
Trial Milestone |
Phase 2 |
| August 24, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| August 24, 2026 |
RGNX |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| August 24, 2026 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| August 24, 2026 |
ORKA |
8-K filed: Leadership change |
Corporate |
— |
| August 24, 2026 |
TLSA |
6-K filed: Foreign issuer report |
Filing |
— |
| August 24, 2026 |
CAPR |
8-K filed: Other event |
Filing |
— |
| August 24, 2026 |
TPST |
8-K filed: Leadership change |
Corporate |
— |
| August 24, 2026 |
ERAS |
8-K filed: Other event |
Filing |
— |
| August 24, 2026 |
ENSC |
8-K filed: Other event |
Filing |
— |
| August 25, 2026 |
AZN |
6-K filed: Corporate announcement |
Corporate |
— |
| August 25, 2026 |
JAZZ |
8-K filed: Other event |
Filing |
— |
| August 25, 2026 |
RGNX |
8-K filed: Leadership change |
Corporate |
— |
| August 25, 2026 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| August 25, 2026 |
BCAX |
8-K filed: Material agreement |
Corporate |
— |
| August 25, 2026 |
SYRE |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| August 25, 2026 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| August 25, 2026 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| August 25, 2026 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| August 25, 2026 |
ENSC |
8-K filed: Other event |
Filing |
— |
| August 26, 2026 |
LLY |
A Study of LY4064912 in Healthy Participants and With Overweight or Obesity |
Trial Milestone |
Phase 1 |
| August 26, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| August 26, 2026 |
ONC |
Quarterly results filed (8-K) |
Earnings |
— |
| August 26, 2026 |
RVMD |
8-K filed: Other event |
Filing |
— |
| August 26, 2026 |
SMMT |
8-K filed: Other event |
Filing |
— |
| August 26, 2026 |
BSX |
8-K filed: Other event |
Filing |
— |
| August 26, 2026 |
GENB |
8-K filed: Reg FD disclosure |
Filing |
— |
| August 26, 2026 |
IMTX |
6-K filed: Foreign issuer report |
Filing |
— |
| August 26, 2026 |
LONA |
8-K filed: Other event |
Filing |
— |
| August 26, 2026 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| August 27, 2026 |
AZN |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| August 27, 2026 |
AMGN |
Effect of Maridebart Cafraglutide on the Heart's Electrical Activity |
Trial Milestone |
Phase 1 |
| August 27, 2026 |
ARGX |
6-K filed: Foreign issuer report |
Filing |
— |
| August 27, 2026 |
BNTX |
6-K filed: Foreign issuer report |
Filing |
— |
| August 27, 2026 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| August 27, 2026 |
MESO |
Results filed (20-F) |
Earnings |
— |
| August 27, 2026 |
MBX |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| August 27, 2026 |
ANRO |
8-K filed: Leadership change |
Corporate |
— |
| August 27, 2026 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| August 27, 2026 |
OTLK |
8-K filed: Leadership change |
Corporate |
— |
| August 28, 2026 |
BMY |
Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome |
Trial Milestone |
Phase 1 |
| August 28, 2026 |
BNTX |
6-K filed: Foreign issuer report |
Filing |
— |
| August 28, 2026 |
INBS |
8-K filed: Reg FD disclosure |
Filing |
— |
| August 28, 2026 |
QNRX |
8-K filed: Material agreement, Reg FD disclosure, Other event |
Corporate |
— |
| August 28, 2026 |
CYTK |
8-K filed: Other event |
Filing |
— |
| August 28, 2026 |
RCUS |
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body |
Trial Milestone |
Phase 3 |
| August 28, 2026 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| August 28, 2026 |
BLRX |
6-K filed: Foreign issuer report |
Filing |
— |
| August 30, 2026 |
GENB |
Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-7624 in Healthy Adult Participants |
Trial Milestone |
Phase 1 |
| August 31, 2026 |
TAK |
6-K filed: Foreign issuer report |
Filing |
— |
| August 31, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| August 31, 2026 |
INCY |
8-K filed: Other event |
Filing |
— |
| August 31, 2026 |
EXEL |
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors |
Trial Milestone |
Phase 1 |
| August 31, 2026 |
EXEL |
8-K filed: Other event |
Filing |
— |
| August 31, 2026 |
JAZZ |
8-K filed: Material agreement, Other event |
Corporate |
— |
| August 31, 2026 |
BMRN |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| August 31, 2026 |
KPTI |
8-K filed: Other event |
Filing |
— |
| August 31, 2026 |
VSTM |
Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer |
Trial Milestone |
Phase 1/Phase 2 |
| August 31, 2026 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| August 31, 2026 |
CYTK |
A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) |
Trial Milestone |
Phase 3 |
| August 31, 2026 |
NRIX |
A Study of NX-1607 in Adults With Advanced Malignancies |
Trial Milestone |
Phase 1 |
| August 31, 2026 |
KYNB |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| August 31, 2026 |
BLRX |
6-K filed: Foreign issuer report |
Filing |
— |
| August 31, 2026 |
BLRX |
6-K filed: Foreign issuer report |
Filing |
— |
| August 31, 2026 |
MBRX |
8-K filed: Reg FD disclosure |
Filing |
— |